194 related articles for article (PubMed ID: 18377416)
1. Molecular biomarkers in urothelial bladder cancer.
Kim WJ; Bae SC
Cancer Sci; 2008 Apr; 99(4):646-52. PubMed ID: 18377416
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic biomarkers in urothelial bladder cancer.
Kim WJ; Kim YJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers in bladder cancer: present status and perspectives.
Kim WJ; Park S; Kim YJ
Biomark Insights; 2007 Mar; 2():95-105. PubMed ID: 19662195
[TBL] [Abstract][Full Text] [Related]
4. Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?
Kim YJ; Kim WJ
Investig Clin Urol; 2016 Jun; 57 Suppl 1(Suppl 1):S77-88. PubMed ID: 27326410
[TBL] [Abstract][Full Text] [Related]
5. Genetic and epigenetic aspects of bladder cancer.
Kim WJ; Quan C
J Cell Biochem; 2005 May; 95(1):24-33. PubMed ID: 15759278
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas.
Mo Q; Nikolos F; Chen F; Tramel Z; Lee YC; Hayashi K; Xiao J; Shen J; Chan KS
J Natl Cancer Inst; 2018 May; 110(5):448-459. PubMed ID: 29342309
[TBL] [Abstract][Full Text] [Related]
7. [Molecular markers for the diagnosis of non-muscle-invasive bladder cancer].
Glybchenko PV; Shakhpazian NK; Ponukalin AN; Zakharova NB
Klin Lab Diagn; 2011 May; (5):16-20. PubMed ID: 21789798
[TBL] [Abstract][Full Text] [Related]
8. Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer.
Dumache R; David D; Kaycsa A; Minciu R; Negru S; Puiu M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):163-7. PubMed ID: 21682190
[TBL] [Abstract][Full Text] [Related]
9. Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis.
Ehdaie B; Theodorescu D
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1103-10. PubMed ID: 18588455
[TBL] [Abstract][Full Text] [Related]
10. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
11. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression.
DeGraff DJ; Cates JM; Mauney JR; Clark PE; Matusik RJ; Adam RM
Urol Oncol; 2013 Aug; 31(6):802-11. PubMed ID: 21924649
[TBL] [Abstract][Full Text] [Related]
12. Fascin determination in urothelial carcinomas of the urinary bladder: a marker of invasiveness.
Karasavvidou F; Barbanis S; Pappa D; Moutzouris G; Tzortzis V; Melekos MD; Koukoulis G
Arch Pathol Lab Med; 2008 Dec; 132(12):1912-5. PubMed ID: 19061289
[TBL] [Abstract][Full Text] [Related]
13. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
14. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling.
van der Kwast TH; Bapat B
Curr Opin Urol; 2009 Sep; 19(5):516-21. PubMed ID: 19553819
[TBL] [Abstract][Full Text] [Related]
15. Epigenetics of bladder cancer.
Kim WJ; Kim YJ
Methods Mol Biol; 2012; 863():111-8. PubMed ID: 22359289
[TBL] [Abstract][Full Text] [Related]
16. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
Yurakh AO; Ramos D; Calabuig-Fariñas S; López-Guerrero JA; Rubio J; Solsona E; Romanenko AM; Vozianov AF; Pellin A; Llombart-Bosch A
Eur Urol; 2006 Sep; 50(3):506-15; discussion 515. PubMed ID: 16624482
[TBL] [Abstract][Full Text] [Related]
17. Current concepts of tumor markers in bladder cancer.
Droller MJ
Urol Clin North Am; 2002 Feb; 29(1):229-34. PubMed ID: 12109349
[TBL] [Abstract][Full Text] [Related]
18. [Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis].
Masson-Lecomte A; Vordos D; de la Taille A; Neuzillet Y; Radvanyi F; Allory Y
Prog Urol; 2013 Feb; 23(2):96-8. PubMed ID: 23352301
[TBL] [Abstract][Full Text] [Related]
19. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
20. Decreased galectin-8 is a strong marker for recurrence in urothelial carcinoma of the bladder.
Kramer MW; Waalkes S; Serth J; Hennenlotter J; Tezval H; Stenzl A; Kuczyk MA; Merseburger AS
Urol Int; 2011; 87(2):143-50. PubMed ID: 21757871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
